表紙:CDMO (医薬品受託製造機関) の世界市場:分析・予測・COVID-19の潜在的影響 (2022-2026年)
市場調査レポート
商品コード
1072731

CDMO (医薬品受託製造機関) の世界市場:分析・予測・COVID-19の潜在的影響 (2022-2026年)

Global Contract Development & Manufacturing Organization (CDMO) Market: Insights & Forecast with Potential Impact of COVID-19 (2022-2026)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 66 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.51円
CDMO (医薬品受託製造機関) の世界市場:分析・予測・COVID-19の潜在的影響 (2022-2026年)
出版日: 2022年05月03日
発行: Koncept Analytics
ページ情報: 英文 66 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のCDMO (医薬品受託製造機関) の市場規模は予測期間中9.31%のCAGRで推移し、2026年には2,466億米ドルの規模に成長すると予測されています。

一人当たりの可処分所得の増加、世界の医療費の増加、高齢化の進展、R&D費の増加、新薬の増加、投資や戦略的提携の増加、医薬品需要の増加などの要因が同市場の成長を推進しています。一方で、政府の厳しい規制が業界の成長を抑制する見通しです。

サービス別では、APIの部門が最大のシェアを示しており、パイプライン段階にある生物製剤のAPIの増加や複数の治療薬の採用が進んでいることから、今後の成長が期待されています。また、製品別では、世界の医薬品R&D活動の活発化に伴い、低分子医薬品が大きなシェアを占めています。

当レポートでは、世界のCDMO (医薬品受託製造機関) の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第1章 CDMO

  • CDMOサービス
  • CDMOの利点

第2章 COVID-19の影響

第3章 世界のCDMO市場の分析

  • 世界のCDMO市場
  • 世界のCDMO市場の予測
  • 世界のCDMO市場・予測:サービス別
    • API/バルク医薬品
    • 医薬品製造
    • 包装
  • 世界のCDMO市場・予測:製品別
    • 生物製剤CDMO
    • 低分子CDMO
  • 世界のCDMO市場・予測:地域別

第4章 CDMO市場の分析:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第5章 市場力学

  • 成長要因
  • 主な動向・展開
  • 課題

第6章 企業プロファイル

  • Catalent, Inc.
  • Recipharm AB
  • Evotec SE
  • Lonza Group AG
  • Biomerieux SA
  • Thermo Fisher Scientific Inc.
図表

List of Figures

  • CDMO Services
  • Number of Clinical Trials for COVID-19 Vaccines and Diagnostic Kits (2020)
  • Global CDMO Market by Value (2017-2021)
  • Global CDMO Market Forecast by Value (2022-2026)
  • Global CDMO Market by Service (2021)
  • Global API/Bulk Drugs Market by Value (2017-2021)
  • Global API/Bulk Drugs Market Forecast by Value (2022-2026)
  • Global Drug Product Manufacturing Market by Value (2017-2021)
  • Global Drug Product Manufacturing Market Forecast by Value (2022-2026)
  • Global Packaging Market by Value (2017-2021)
  • Global Packaging Market Forecast by Value (2022-2026)
  • Global CDMO Market by Product (2021)
  • Global Biologics CDMO Market by Value (2017-2021)
  • Global Biologics CDMO Market Forecast by Value (2022-2026)
  • Global Small Molecule CDMO Market by Value (2017-2021)
  • Global Small Molecule CDMO Market Forecast by Value (2022-2026)
  • Global CDMO Market by Region (2021)
  • North America CDMO Market by Value (2017-2021)
  • North America CDMO Market Forecast by Value (2022-2026)
  • Europe CDMO Market by Value (2017-2021)
  • Europe CDMO Market Forecast by Value (2022-2026)
  • Asia Pacific CDMO Market by Value (2017-2021)
  • Asia Pacific CDMO Market Forecast by Value (2022-2026)
  • Latin America CDMO Market by Value (2017-2021)
  • Latin America CDMO Market Forecast by Value (2022-2026)
  • Middle East & Africa CDMO Market by Value (2017-2021)
  • Middle East & Africa CDMO Market Forecast by Value (2022-2026)
  • Global GNI Per Capita (2015-2019)
  • Global Healthcare Expenditure Per Capita (2017-2021)
  • Global Aging Population (2017-2021)
  • Global Pharmaceutical R&D Expenditure (2022-2026)
  • FDA Approval of Chemical NMEs and Biologics (2015-2019)
目次

The global CDMO market is estimated to reach US$246.6 billion in 2026, growing at a CAGR of 9.31%, for the period spanning 2022-2026. The factors such as increasing per capita disposable income, increasing global healthcare expenditure, rising aging population, increasing R&D spending, growing number of new drugs, rise in investments and strategic collaborations and growing demand for pharmaceutical products are expected to drive the market. However, growth of the industry will be challenged by stringent government regulations. A few notable trends include increasing demand for highly potent API manufacturing services, growing demand for quality by design services, growth in oncology segment, growing demand for process development CDMO services and lengthy and costly drug development process.

In terms of services, the global API drug market accounted for the highest share of the market and is expected to grow in future owing to growing number of biologics APIs in pipeline stage and growing adoption of multiple of therapies. Whereas on the basis of product, Small molecule drugs held a major share of the market owing to the surge in the pharmaceutical R&D activities worldwide.

In terms of geographical areas, North America is the major contributor to the global CDMO market supported by growing collaborations and wide range of services provided by CDMOs. Asia Pacific is the fastest growing market for CDMOs owing to highly skilled workforce and low research and development cost advantage.

Scope of the report:

  • The report provides a comprehensive analysis of the global CDMO industry.
  • The major regional markets (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The company profiles of leading players (Catalent, Inc., Recipharm AB, Evotec SE, Lonza Group AG, Biomerieux SA and Thermo Fisher Scientific Inc.) are also presented in detail.

Key Target Audience:

  • Contract Manufacturing Organization
  • Pharmaceutical Companies
  • Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Introduction

1. CDMO

  • 1.2 CDMO Services
  • 1.3 Advantages of CDMO

2. Impact of COVID-19

  • 2.1 Rise in Clinical Trials

3. Global CDMO Market Analysis

  • 3.1 Global CDMO Market by Value
  • 3.2 Global CDMO Market Forecast by Value
  • 3.3 Global CDMO Market by Service
    • 3.3.1 Global API/Bulk Drugs Market by Value
    • 3.3.2 Global API/Bulk Drugs Market Forecast by Value
    • 3.3.3 Global Drug Product Manufacturing Market by Value
    • 3.3.4 Global Drug Product Manufacturing Market Forecast by Value
    • 3.3.5 Global Packaging Market by Value
    • 3.3.6 Global Packaging Market Forecast by Value
  • 3.4 Global CDMO Market by Product
    • 3.4.1 Global Biologics CDMO Market by Value
    • 3.4.2 Global Biologics CDMO Market Forecast by Value
    • 3.4.3 Global Small Molecule CDMO Market by Value
    • 3.4.4 Global Small Molecule CDMO Market Forecast by Value
  • 3.5 Global CDMO Market by Region

4. Regional CDMO Market Analysis

  • 4.1 North America
    • 4.1.1 North America CDMO Market by Value
    • 4.1.2 North America CDMO Market Forecast by Value
  • 4.2 Europe
    • 4.2.1 Europe CDMO Market by Value
    • 4.2.2 Europe CDMO Market Forecast by Value
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific CDMO Market by Value
    • 4.3.2 Asia Pacific CDMO Market Forecast by Value
  • 4.4 Latin America
    • 4.4.1 Latin America CDMO Market by Value
    • 4.4.2 Latin America CDMO Market Forecast by Value
  • 4.5 Middle East & Africa
    • 4.5.1 Middle East & Africa CDMO Market by Value
    • 4.5.2 Middle East & Africa CDMO Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Increasing Per Capita Disposable Income
    • 5.1.2 Increasing Global Healthcare Expenditure
    • 5.1.3 Rising Aging Population
    • 5.1.4 Increasing R&D Spending
    • 5.1.5 Growing Number of New Drugs
    • 5.1.6 Rise in Investments and Strategic Collaborations
    • 5.1.7 Growing Demand for Pharmaceutical Products
  • 5.2 Key Trends & Developments
    • 5.2.1 Increasing Demand for Highly Potent API Manufacturing Services
    • 5.2.2 Growing Demand for Quality by Design Services
    • 5.2.3 Growth in Oncology Segment
    • 5.2.4 Growing Demand for Process Development CDMO Services
    • 5.2.5 Lengthy and Costly Drug Development Process
  • 5.3 Challenges
    • 5.3.1 Stringent Government Regulations

6. Company Profiles

  • 6.1 Catalent, Inc.
    • 6.1.1 Business Overview
  • 6.2 Recipharm AB
    • 6.2.1 Business Overview
  • 6.3 Evotec SE
    • 6.3.1 Business Overview
  • 6.4 Lonza Group AG
    • 6.4.1 Business Overview
  • 6.5 Biomerieux SA
    • 6.5.1 Business Overview
  • 6.6 Thermo Fisher Scientific Inc.
    • 6.6.1 Business Overview